Form 8-K - Current report:
SEC Accession No. 0000950170-25-040758
Filing Date
2025-03-18
Accepted
2025-03-18 07:05:09
Documents
13
Period of Report
2025-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stok-20250318.htm   iXBRL 8-K 56070
2 EX-99.1 stok-ex99_1.htm EX-99.1 257878
3 EX-99.2 stok-ex99_2.htm EX-99.2 27735
  Complete submission text file 0000950170-25-040758.txt   476699

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20250318.xsd EX-101.SCH 23933
15 EXTRACTED XBRL INSTANCE DOCUMENT stok-20250318_htm.xml XML 4523
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 25746477
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)